Trilaciclib Increases Pool of Memory T Cells in the Tumor Mi

- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microe...

Related Keywords

United States , American , Raj Malik , Therapeutics Inc , Investor Relations Corporate Communications , Exchange Commission , Research Triangle Park , American Joint Committee On Cancer , American Society Of Clinical Oncology , Nasdaq , Action Trial Results Demonstrate , Immunomodulatory Effects , Tumor Microenvironment , Enhances Expression , Genes Associated , Memoryt Cells , Increases Multiple Surrogate Immune Markers , Chief Medical Officer , Clinical Oncology , Early Triple Negative Breast Cancer , Immune Correlate Data , Clinical Outcome , Pathologic Complete Response , Action Trial , American Joint Committee , Private Securities Litigation Reform Act , Investor Relations ,